New Data Links Wegovy to Higher Risk of Rare Vision Loss: What Patients Need to Know

March 12, 2026

Recent findings published in the British Journal of Ophthalmology have introduced a sobering note to the ongoing success story of GLP-1 weight-loss medications. A comprehensive analysis of global safety data indicates that Wegovy, the high-dose semaglutide injection approved for obesity, is associated with a significantly higher risk of a rare but debilitating condition known as ischemic optic neuropathy (ION)—often referred to as an “eye stroke”—compared to other medications in its class.

The study, which examined over 30 million adverse event reports from the U.S. Food and Drug Administration (FDA) between 2017 and 2024, found that Wegovy users faced odds of developing ION nearly five times higher than those taking Ozempic, a lower-dose version of the same drug. With millions of prescriptions being written globally, medical experts are now calling for increased vigilance and better patient screening to balance the drug’s profound metabolic benefits against these rare ocular risks.

Unpacking the “Eye Stroke” Connection

Ischemic optic neuropathy occurs when blood flow to the optic nerve is interrupted, leading to sudden, painless, and often permanent vision loss. While rare in the general population, the condition is devastating because there are currently few effective treatments to restore lost sight.

The researchers, led by P. Upadhyaya, specifically targeted reports involving semaglutide formulations: Ozempic (injectable for type 2 diabetes), Wegovy (injectable for obesity), and Rybelsus (the oral tablet version).

The data revealed a striking “dose-response” signal:

• Wegovy: Linked to 28 cases of ION with odds 75 times higher than non-GLP-1 comparator drugs.

• Ozempic: Linked to 47 cases with odds 19 times higher than comparators.

• Oral Rybelsus & Tirzepatide (Mounjaro/Zepbound): No significant ION signals were detected.

The discrepancy between Wegovy and Ozempic is particularly noteworthy because both contain the same active ingredient, semaglutide. However, Wegovy is administered at a higher maximum weekly dose ($2.4$ mg) compared to Ozempic ($2.0$ mg). The study also highlighted a significant gender gap, finding that men using Wegovy faced odds of ION more than three times higher than women on the same medication.

Why Is This Happening?

While the study establishes a statistical association, it does not prove that Wegovy causes ION. However, researchers have several hypotheses. The optic nerve requires a steady, sensitive supply of blood. High-dose injectables like Wegovy may lead to “hypoperfusion”—a state of decreased blood flow—possibly triggered by rapid changes in blood pressure, volume contraction (dehydration), or autonomic nervous system instability as the body adjusts to the medication.

“The dose-dependent signal we are seeing with Wegovy is concerning,” says Dr. Elena Rossi, an ophthalmologist at Massachusetts General Hospital who was not involved in the study. “While ION remains an extremely rare event, these findings suggest that the speed and concentration of the drug delivery might play a role in how it affects the vascular health of the eye.”

Expert Perspectives: A “Gathering Storm”?

The medical community has been monitoring this link since a 2024 JAMA Ophthalmology report first flagged a potential connection. By 2025, the World Health Organization (WHO) issued a formal alert, urging patients to seek immediate medical attention if they experience sudden changes in vision.

In a commentary linked to the new study, experts described a “gathering storm” of ocular considerations. As GLP-1 drugs expand into new territories—such as treating cardiovascular disease, dementia, and even pediatric obesity—the number of people exposed to these risks is set to skyrocket.

“We are in an era of ‘blockbuster’ outcomes for weight loss,” Dr. Rossi explains. “But for a patient who already has vascular risk factors like high blood pressure or sleep apnea, the conversation about starting Wegovy needs to include a discussion about eye health.”

Putting the Risk in Perspective

It is essential for patients to view these findings through a balanced lens. For most, the benefits of semaglutide—including a $15\%$–$20\%$ reduction in body weight and significant decreases in the risk of heart attack and stroke—far outweigh the slim probability of a rare eye condition.

The background rate of ION in the general population is estimated at only $2$ to $10$ cases per $100,000$ people annually. Even with a five-fold increase in relative risk, the absolute risk for an individual remains very low. Furthermore, clinical trials (RCTs), which are the gold standard for medical evidence, have not yet shown a definitive increase in ION, though critics argue those trials may not be long enough or large enough to catch such rare events.

Limitations of the Study

The researchers utilized the FDA’s Adverse Event Reporting System (FAERS). This database relies on voluntary reporting from doctors and patients, which can lead to:

1. Reporting Bias: Media coverage of Wegovy might encourage more people to report side effects.

2. Missing Context: Reports often lack detailed patient histories, such as pre-existing heart conditions or smoking habits, which also contribute to vision loss.

3. Causality: Observational data can show that two things happen at the same time, but it cannot confirm that one caused the other.

Guidance for Patients and Providers

The findings suggest a shift toward more personalized medicine in the obesity treatment space. Rather than a one-size-fits-all approach, healthcare providers may need to integrate ocular health into their screening process.

For Patients:

• Don’t Panic, but Be Proactive: If you are currently taking Wegovy and have no vision issues, there is no need to stop the medication abruptly.

• Monitor Your Sight: Seek immediate care if you notice sudden blurred vision, “shadows” in your field of vision, or dark spots.

• Baseline Exams: If you have a history of glaucoma or optic nerve issues, consider a comprehensive eye exam before starting high-dose GLP-1 therapy.

For Healthcare Providers:

• Risk Assessment: Consider lower-dose options or oral formulations for patients at high risk for vascular issues.

• Informed Consent: Ensure patients are aware of the rare potential for ocular side effects as part of the standard counseling for weight-loss injections.

As these “miracle drugs” continue to reshape public health, this study serves as a reminder that every potent medical intervention carries a profile of risks that must be carefully managed. For now, the “eye stroke” remains a rare complication, but one that requires both patients and doctors to keep a watchful eye on the horizon.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Upadhyaya P, et al. (2026). “Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.” British Journal of Ophthalmology. DOI: 10.1136/bjo-2025-328483.